JP2015096544A5 - - Google Patents

Download PDF

Info

Publication number
JP2015096544A5
JP2015096544A5 JP2015000566A JP2015000566A JP2015096544A5 JP 2015096544 A5 JP2015096544 A5 JP 2015096544A5 JP 2015000566 A JP2015000566 A JP 2015000566A JP 2015000566 A JP2015000566 A JP 2015000566A JP 2015096544 A5 JP2015096544 A5 JP 2015096544A5
Authority
JP
Japan
Prior art keywords
tumor
group
medicament
compound
ratios
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015000566A
Other languages
English (en)
Japanese (ja)
Other versions
JP5997782B2 (ja
JP2015096544A (ja
Filing date
Publication date
Priority claimed from DE102007047738A external-priority patent/DE102007047738A1/de
Application filed filed Critical
Publication of JP2015096544A publication Critical patent/JP2015096544A/ja
Publication of JP2015096544A5 publication Critical patent/JP2015096544A5/ja
Application granted granted Critical
Publication of JP5997782B2 publication Critical patent/JP5997782B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015000566A 2007-10-05 2015-01-05 イミダゾール誘導体 Expired - Fee Related JP5997782B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007047738.6 2007-10-05
DE102007047738A DE102007047738A1 (de) 2007-10-05 2007-10-05 Imidazolderivate

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010527344A Division JP5725860B2 (ja) 2007-10-05 2008-09-09 イミダゾール誘導体

Publications (3)

Publication Number Publication Date
JP2015096544A JP2015096544A (ja) 2015-05-21
JP2015096544A5 true JP2015096544A5 (enExample) 2015-07-30
JP5997782B2 JP5997782B2 (ja) 2016-09-28

Family

ID=40151186

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010527344A Expired - Fee Related JP5725860B2 (ja) 2007-10-05 2008-09-09 イミダゾール誘導体
JP2015000566A Expired - Fee Related JP5997782B2 (ja) 2007-10-05 2015-01-05 イミダゾール誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010527344A Expired - Fee Related JP5725860B2 (ja) 2007-10-05 2008-09-09 イミダゾール誘導体

Country Status (16)

Country Link
US (1) US20100249132A1 (enExample)
EP (1) EP2193122B1 (enExample)
JP (2) JP5725860B2 (enExample)
KR (1) KR20100075602A (enExample)
CN (1) CN101809001B (enExample)
AR (1) AR068659A1 (enExample)
AU (1) AU2008310117B2 (enExample)
BR (1) BRPI0817609A2 (enExample)
CA (1) CA2701568C (enExample)
DE (1) DE102007047738A1 (enExample)
EA (1) EA201000558A1 (enExample)
ES (1) ES2601139T3 (enExample)
IL (1) IL204683A (enExample)
MX (1) MX2010003368A (enExample)
WO (1) WO2009046804A1 (enExample)
ZA (1) ZA201003125B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009049211A1 (de) * 2009-10-13 2011-04-28 Merck Patent Gmbh Sulfoxide
US9249087B2 (en) 2011-02-01 2016-02-02 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
WO2012127885A1 (ja) 2011-03-18 2012-09-27 小野薬品工業株式会社 テトラヒドロカルボリン誘導体
ES2748656T3 (es) * 2011-10-28 2020-03-17 Inhibitaxin Ltd Derivados de piridazina útiles en terapia
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
EP2935249B1 (en) 2012-12-19 2018-12-12 Novartis AG Autotaxin inhibitors
EP3022201A1 (en) * 2013-07-18 2016-05-25 Novartis AG Autotaxin inhibitors
PT3022202T (pt) 2013-07-18 2019-09-03 Novartis Ag Inibidores da autotaxina compreendendo um núcleo beteroaromático anel-benzilo-amida-ciclo
KR102367876B1 (ko) 2013-11-22 2022-02-24 사브레 테라퓨틱스 엘엘씨 오토탁신 억제제 화합물
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
CN107074822B (zh) * 2014-09-15 2020-01-03 爱杜西亚药品有限公司 作为t型钙通道阻断剂的三唑化合物
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
EA036337B1 (ru) 2015-05-27 2020-10-28 Сабре Терапьютикс Ллс Ингибиторы аутотаксина и их применения
CA2988306A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2022026867A1 (en) * 2020-07-31 2022-02-03 Cedars-Sinai Medical Center Glutamine as an anticancer therapy in solid tumors
EP4197596A1 (en) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Imidazole derivatives for the treatment and prophylaxis of infectious diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
AU4972900A (en) 1999-04-08 2000-11-14 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
DE19954707A1 (de) * 1999-11-13 2001-05-17 Merck Patent Gmbh Imidazolverbindungen als Phosphodiesterase VII-Hemmer
PT1258484E (pt) * 2000-02-18 2009-04-03 Kyowa Hakko Kirin Co Ltd Novos compostos de isoxazol e de tiazol e sua utilização enquanto fármacos
FR2889190A1 (fr) * 2005-08-01 2007-02-02 Merck Sante Soc Par Actions Si Nouveaux derives d'imidazoles carboxamides comme inhibiteurs de fructose -1,6-biphosphatase et compositions pharmaceutiques les contenant

Similar Documents

Publication Publication Date Title
JP2018510191A5 (enExample)
HRP20130929T1 (hr) Derivati piperidina i piperazina za lijeäśenje tumora
RU2018105655A (ru) Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака
JP2018516963A5 (enExample)
HRP20160361T1 (hr) Terapija u kombinaciji s antitumorskim alkaloidom
JP2015523397A5 (enExample)
JP2018109022A5 (enExample)
JP2015536964A5 (enExample)
JP2016528162A5 (enExample)
JP2016528246A5 (enExample)
JP2015512398A5 (enExample)
RU2014128513A (ru) Раковый маркер и терапевтическая мишень
JP2017530184A5 (enExample)
JP2017516781A5 (enExample)
TW201613589A (en) Combination methods for treating cancers
MX2019002066A (es) Regimen de dosificacion para el tratamiento de tumores solidos.
JP2015517523A5 (enExample)
JP2009539994A5 (enExample)
JP2019510075A5 (enExample)
JP2008514577A5 (enExample)
JP2021105005A5 (enExample)
JP2009536956A5 (enExample)
CN110494131A (zh) 精胺及其衍生物在制备抗肿瘤药物中的应用
CN111867629A (zh) 抗her2抗体-药物偶联物在治疗癌症中的用途
RU2018131573A (ru) Способ лечения больных раком с тяжелой почечной недостаточностью